Navigation Links
Cephalon Wins FENTORA Patent Suit Against Watson
Date:3/24/2011

FRAZER, Pa., March 24, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced that today the United States District Court in Delaware upheld the validity of Cephalon's U.S. Patent Number 6,264,981 patent and found that Watson Pharmaceuticals, Inc.'s proposed generic version of FENTORA® (fentanyl buccal tablet) infringes that patent.  The Court also denied Watson's motion to vacate a previously entered injunction preventing Watson from marketing its product.

"We are pleased with the court's ruling upholding the validity of our patent, as well as its finding that Watson's product infringes that patent," said Jerry Pappert, Executive Vice President and General Counsel of Cephalon.  

This decision pertained to patent litigation brought by Cephalon and its wholly-owned subsidiary CIMA Labs, Inc., against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., regarding Cephalon's FENTORA product.  

FENTORA was approved by the U.S. Food and Drug Administration (FDA) in September 2006.

About Cephalon, Inc.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cepha
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Definitive Agreement to Acquire Gemin X
2. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
3. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
4. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
5. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
6. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
7. Cephalon to Webcast Investor Day
8. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
9. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
10. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
11. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
(Date:9/18/2014)... , Sept. 18, 2014 Just days before ... a three-day quarantine to contain the spread of Ebola, World ... medical relief supplies – thanks to private donations. ... United States , through its affiliate McKesson Medical-Surgical donated ... the entire country of Sierra Leone,s ...
(Date:9/17/2014)... Sept. 17, 2014 North America Gynecological ... GlobalData,s new report, "North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3
... Bias, DURHAM, N.C., Sept. 15 Less ... treatment are eventually published in,medical journals, according to ... Oncologist.", (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), ... of Washington and,Fred Hutchinson Cancer Research Center, Seattle, ...
... a novel ... macrolide-related drug class, WATERTOWN, Mass., Sept. ... molecule anti-infective drugs, announced,today the initiation of a Phase 1 ... novel,macrolide-related drug class with a distinct resistance profile. The,clinical development ...
Cached Medicine Technology:Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 2Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 3
(Date:9/18/2014)... 2014 Pathways Home Health & ... position of Chief Medical Director. Prior to accepting ... Pathways programs including Pathways KIDS, adult palliative care, and ... and Santa Clara Counties. , In her new ... Pathway’s patient care program. She will supervise five medical ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Imaging technology has ... stress disorder (PTSD) manifest in the brain, according to ... health condition that can cause a wide range of ... being in a constant state of stress and avoiding ... the study. Researchers identified a specific opioid receptor ...
(Date:9/18/2014)... 2014 -- Only about half of all pregnant women ... thousands of moms-to-be and their babies at increased risk of ... be a routine part of prenatal care," said Edward McCabe, ... should offer their pregnant patients a flu shot each year ... , A report by the U.S. Centers for Disease Control ...
(Date:9/18/2014)... in disadvantaged neighborhoods have worse musculoskeletal pain outcomes ... vehicle collision than individuals from higher socioeconomic status ... as age, sex, income, education, and employment status. ... research study led by Samuel McLean, MD, MPH, ... the University of North Carolina School of Medicine. ...
(Date:9/18/2014)... COPENHAGEN, Denmark and CAMBRIDGE, Massachusetts, U.S.A., September 18, ... Tech) is providing sequencing service to Denmark-based DLF-Trifolium ... (MBG) at Aarhus University in an effort to ... varieties by employing genomic selection (GS) methods. , ... selection, which in contrast to the traditional QTL-based ...
Breaking Medicine News(10 mins):Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 3Health News:Flu vaccine for expectant moms a top priority 2Health News:Living in a disadvantaged neighborhood worsens musculoskeletal pain outcomes after trauma 2Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2
... representing the Women,s Dermatologic Society (WDS) will, help Texan ... skin cancer screenings and sun safety tips ... Texas, Sept. 18 Even though higher altitudes,mean heightened ... enjoying the upcoming Plano Hot Air Balloon Festival will ...
... cells and other tissue in the laboratory in conditions similar ... , The technology, developed and patented by scientists at Durham ... scaffold which allows cells to be grown in a more ... of a Petri dish. , Evidence gathered by the ...
... that training programs for females to restore balance between ... could help reduce the disproportionately high number of ACL ... shows that the amount of preparatory muscle action in ... is associated with knee positions that are considered at ...
... for Treating Major Symptoms of Lumbar ... ... KYPH ) today announced that Dr. Michael Marks, orthopaedic spine,surgeon from ... will be interviewed together on,American Health Radio, the nationally-syndicated health radio ...
... 18 AMERIGROUP,Corporation (NYSE: AGP ) today ... Centers for Medicaid and Medicare Services (CMS) to ... traditional Medicare,Advantage health plans to address the specialized ... states. AMERIGROUP currently coordinates care for approximately ...
... heard,arguments yesterday in the lawsuit brought in Superior Court ... time during the,U.S. Medical Licensing Examination (USMLE). "Fairness ... remain the,overriding concerns of the exam,s sponsors," said Joseph ... Examiners, which co-sponsors the,exam and was named in the ...
Cached Medicine News:Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 2Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 3Health News:Cell growth technology promises more successful drug development 2Health News:Cell growth technology promises more successful drug development 3Health News:Muscle patterns in women may be linked to at risk positioning for ACL tears 2Health News:Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007 2Health News:Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007 3Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 2Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 3Health News:Massachusetts State Court Hears Suit by Breastfeeding Mother on Medical Licensing Exam 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: